Polypharmacy of schizophrenia

Psychiatry (Edgemont)

Volumn 7, Issue 8, 2010, Pages 17-19

  Dussias, Peter ^a   Kalali, Amir H ^b   Citrome, Leslie ^c  

^a IQVIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c NATHAN S KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH   (United States)

Author keywords

Antidepressants; Antipsychotics; Extrapyramidal symptoms; Mood stabilizers; Schizophrenia

Indexed keywords

ANOREXIGENIC AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; LITHIUM; MOOD STABILIZER; NEUROLEPTIC AGENT;

AGGRESSIVENESS; AKATHISIA; ARTICLE; CHRONICITY; COGNITIVE DEFECT; DISEASE SEVERITY; DRUG CHOICE; DRUG CLASSIFICATION; DRUG UTILIZATION; EVIDENCE BASED MEDICINE; EXTRAPYRAMIDAL SYNDROME; HUMAN; LONG TERM CARE; MENTAL INSTABILITY; NEGATIVE SYNDROME; PATIENT ATTITUDE; POLYPHARMACY; PSYCHOSIS; SCHIZOPHRENIA; SIDE EFFECT; WEIGHT GAIN;

EID: 78650054446     PISSN: 15505952     EISSN: 15555194     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Citrome L, Levine J, Allingham B. Changes in use of valproate and other mood stabilizers for patients with schizophrenia from 1994 to 1998. Psychiatr Serv. 2000;51(5):634-638.
2. Jaffe AB, Levine J. Antipsychotic medication coprescribing in a large state hospital system. Pharmacoepidemiol Drug Saf. 2003;12(1):41-48.
3. Correll CU, Rummel-Kluge, Corves C, et al. Antipsychotic combination vs monotherapy in schizophrenia: a meta-analysis of randomized controlled trials. Schizophr Bull. 2009;35(2):443-457.
4. Fleschhacker WW, Heikkinen ME, Olié JP, et al. Effects of adjunctive treatment with aripiprazole on body weight and clinical efficacy in schizophrenia patients treated with clozapine: a randomized, doubleblind, placebo-controlled trial. Int J Neuropsychopharmacol. 2010;13(8):1115-1125.
5. Citrome L. Adjunctive lithium and anticonvulsants for the treatment of schizophrenia: what is the evidence? Expert Rev Neurother. 2009;9(1):55-71.
6. Citrome L, Goldberg JF, Stahl SM. Toward convergence in the medication treatment of bipolar disorder and schizophrenia. Harv Rev Psychiatry. 2005;13(1):28-42.
7. Buchanan RW, Javitt DC, Marder SR, et al. The cognitive and negative symptoms in schizophrenia trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments. Am J Psychiatry. 2007;164(10):1593-1602.
8. Freudenreich O, Henderson DC, Macklin EA, et al. Modafinil for clozapine-treated schizophrenia patients: a double-blind, placebocontrolled pilot trial. J Clin Psychiatry. 2009;70(12):1674-1680.
9. Kelly DL, Buchanan RW, Boggs DL, et al. A randomized double-blind trial of atomoxetine for cognitive impairments in 32 people with schizophrenia. J Clin Psychiatry. 2009;70(4):518-525.
10. Lieberman JA, Papadakis K, Csernansky J, et al. A randomized, placebo-controlled study of memantine as adjunctive treatment in patients with schizophrenia. Neuropsychopharmacology. 2009;34(5):1322-1329.
11. Piskuliç D, Olver JS, Maruff P, Norman TR. Treatment of cognitive dysfunction in chronic schizophrenia by augmentation of atypical antipsychotics with buspirone, a partial 5-HT(1A) receptor agonist. Hum Psychopharmacol. 2009;24(6):437-446.
12. Javitt DC. Glutamate as a therapeutic target in psychiatric disorders. Mol Psychiatry. 2004;9(11):984-997, 979.